These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 27602582)

  • 1. Discovery and clinical introduction of first-in-class imipridone ONC201.
    Allen JE; Kline CL; Prabhu VV; Wagner J; Ishizawa J; Madhukar N; Lev A; Baumeister M; Zhou L; Lulla A; Stogniew M; Schalop L; Benes C; Kaufman HL; Pottorf RS; Nallaganchu BR; Olson GL; Al-Mulla F; Duvic M; Wu GS; Dicker DT; Talekar MK; Lim B; Elemento O; Oster W; Bertino J; Flaherty K; Wang ML; Borthakur G; Andreeff M; Stein M; El-Deiry WS
    Oncotarget; 2016 Nov; 7(45):74380-74392. PubMed ID: 27602582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies.
    Prabhu VV; Talekar MK; Lulla AR; Kline CLB; Zhou L; Hall J; Van den Heuvel APJ; Dicker DT; Babar J; Grupp SA; Garnett MJ; McDermott U; Benes CH; Pu JJ; Claxton DF; Khan N; Oster W; Allen JE; El-Deiry WS
    Cell Cycle; 2018; 17(4):468-478. PubMed ID: 29157092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ONC201 and imipridones: Anti-cancer compounds with clinical efficacy.
    Prabhu VV; Morrow S; Rahman Kawakibi A; Zhou L; Ralff M; Ray J; Jhaveri A; Ferrarini I; Lee Y; Parker C; Zhang Y; Borsuk R; Chang WI; Honeyman JN; Tavora F; Carneiro B; Raufi A; Huntington K; Carlsen L; Louie A; Safran H; Seyhan AA; Tarapore RS; Schalop L; Stogniew M; Allen JE; Oster W; El-Deiry WS
    Neoplasia; 2020 Dec; 22(12):725-744. PubMed ID: 33142238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212.
    Wagner J; Kline CL; Ralff MD; Lev A; Lulla A; Zhou L; Olson GL; Nallaganchu BR; Benes CH; Allen JE; Prabhu VV; Stogniew M; Oster W; El-Deiry WS
    Cell Cycle; 2017 Oct; 16(19):1790-1799. PubMed ID: 28489985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
    Allen JE; Krigsfeld G; Patel L; Mayes PA; Dicker DT; Wu GS; El-Deiry WS
    Mol Cancer; 2015 May; 14():99. PubMed ID: 25927855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of ONC201 and TLY012 induces selective, synergistic apoptosis in vitro and significantly delays PDAC xenograft growth in vivo.
    Jhaveri AV; Zhou L; Ralff MD; Lee YS; Navaraj A; Carneiro BA; Safran H; Prabhu VV; Ross EA; Lee S; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):607-618. PubMed ID: 34856854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors.
    Prabhu VV; Lulla AR; Madhukar NS; Ralff MD; Zhao D; Kline CLB; Van den Heuvel APJ; Lev A; Garnett MJ; McDermott U; Benes CH; Batchelor TT; Chi AS; Elemento O; Allen JE; El-Deiry WS
    PLoS One; 2017; 12(8):e0180541. PubMed ID: 28767654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-Molecule ONC201/TIC10 Targets Chemotherapy-Resistant Colorectal Cancer Stem-like Cells in an Akt/Foxo3a/TRAIL-Dependent Manner.
    Prabhu VV; Allen JE; Dicker DT; El-Deiry WS
    Cancer Res; 2015 Apr; 75(7):1423-32. PubMed ID: 25712124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ONC201 Targets AR and AR-V7 Signaling, Reduces PSA, and Synergizes with Everolimus in Prostate Cancer.
    Lev A; Lulla AR; Ross BC; Ralff MD; Makhov PB; Dicker DT; El-Deiry WS
    Mol Cancer Res; 2018 May; 16(5):754-766. PubMed ID: 29588330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitochondrial Protease ClpP is a Target for the Anticancer Compounds ONC201 and Related Analogues.
    Graves PR; Aponte-Collazo LJ; Fennell EMJ; Graves AC; Hale AE; Dicheva N; Herring LE; Gilbert TSK; East MP; McDonald IM; Lockett MR; Ashamalla H; Moorman NJ; Karanewsky DS; Iwanowicz EJ; Holmuhamedov E; Graves LM
    ACS Chem Biol; 2019 May; 14(5):1020-1029. PubMed ID: 31021596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-In-Class Small Molecule ONC201 Induces DR5 and Cell Death in Tumor but Not Normal Cells to Provide a Wide Therapeutic Index as an Anti-Cancer Agent.
    Allen JE; Crowder RN; El-Deiry WS
    PLoS One; 2015; 10(11):e0143082. PubMed ID: 26580220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumorigenic effect of combination treatment with ONC201 and TRAIL in endometrial cancer
    Ray JE; Ralff MD; Jhaveri A; Zhou L; Dicker DT; Ross EA; El-Deiry WS
    Cancer Biol Ther; 2021 Dec; 22(10-12):554-563. PubMed ID: 34696710
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ONC201 induces cell death in pediatric non-Hodgkin's lymphoma cells.
    Talekar MK; Allen JE; Dicker DT; El-Deiry WS
    Cell Cycle; 2015 Aug; 14(15):2422-8. PubMed ID: 26030065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer.
    Farmaki E; Nath A; Emond R; Karimi KL; Grolmusz VK; Cosgrove PA; Bild AH
    Elife; 2023 Sep; 12():. PubMed ID: 37772709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Imipridone ONC201 Induces Apoptosis and Overcomes Chemotherapy Resistance by Up-Regulation of Bim in Multiple Myeloma.
    Tu YS; He J; Liu H; Lee HC; Wang H; Ishizawa J; Allen JE; Andreeff M; Orlowski RZ; Davis RE; Yang J
    Neoplasia; 2017 Oct; 19(10):772-780. PubMed ID: 28863346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.
    Allen JE; Krigsfeld G; Mayes PA; Patel L; Dicker DT; Patel AS; Dolloff NG; Messaris E; Scata KA; Wang W; Zhou JY; Wu GS; El-Deiry WS
    Sci Transl Med; 2013 Feb; 5(171):171ra17. PubMed ID: 23390247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases.
    Kline CL; Van den Heuvel AP; Allen JE; Prabhu VV; Dicker DT; El-Deiry WS
    Sci Signal; 2016 Feb; 9(415):ra18. PubMed ID: 26884600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells.
    Bonner ER; Waszak SM; Grotzer MA; Mueller S; Nazarian J
    Neuro Oncol; 2021 Apr; 23(4):542-556. PubMed ID: 33336683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of Dopamine Receptors in the Anticancer Activity of ONC201.
    Kline CLB; Ralff MD; Lulla AR; Wagner JM; Abbosh PH; Dicker DT; Allen JE; El-Deiry WS
    Neoplasia; 2018 Jan; 20(1):80-91. PubMed ID: 29216597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.